Pourafkari Leili, Visnjevac Ognjen, Ghaffari Samad, Nader Nader D
Cardovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran ; State University of New York at Buffalo, Buffalo, NY, USA.
State University of New York at Buffalo, Buffalo, NY, USA.
J Cardiovasc Thorac Res. 2016;8(1):34-9. doi: 10.15171/jcvtr.2016.06. Epub 2016 Mar 15.
The objective was to examine the role of statins in modulating post-STEMI inflammation and related mortality.
A total of 404 patients with STEMI were reviewed. Demographics, comorbidities, laboratory values, and outcomes were collected. The patients were grouped as STATIN and NOSTAT based on the use of statin drugs at the time of admission. Ninety-seven patients were receiving statin drugs.
The patients in the STATIN group were more likely to be hypertensive (53.6%), diabetic (37.1%) and to have previous coronary revascularization (9.3%). Following propensity matching of 89 patients in STATIN group to an equal number of patients in NOSTAT controls had lower neutrophil count 7.8 (6.8-8.4) compared to those in the NOSTAT group 9.1 (7.9-10.1). Although there was no difference in-hospital mortality between the two groups, the incidence of pump failure was lower in the STATIN group (5.6% vs. 15.7%; P < 0.01).
Statin treatment prior to STEMI mitigates the cellular inflammatory response after the myocardial infarction, as evidenced by lower leukocyte and neutrophil cell counts in the STATIN group.
目的是研究他汀类药物在调节ST段抬高型心肌梗死（STEMI）后炎症反应及相关死亡率方面的作用。
共纳入404例STEMI患者进行回顾性分析。收集患者的人口统计学资料、合并症、实验室检查值及预后情况。根据入院时是否使用他汀类药物将患者分为他汀类药物组（STATIN）和非他汀类药物组（NOSTAT）。其中97例患者正在接受他汀类药物治疗。
STATIN组患者更易患高血压（53.6%）、糖尿病（37.1%），且既往有冠状动脉血运重建史（9.3%）。在将STATIN组的89例患者与同等数量的NOSTAT组患者进行倾向评分匹配后，发现STATIN组患者的中性粒细胞计数为7.8（6.8 - 8.4），低于NOSTAT组的9.1（7.9 - 10.1）。尽管两组患者的院内死亡率无差异，但STATIN组的心衰发生率较低（5.6%对15.7%；P < 0.01）。
STEMI前使用他汀类药物治疗可减轻心肌梗死后的细胞炎症反应，STATIN组白细胞和中性粒细胞计数较低证明了这一点。
